Huons Global Co (084110) Fair Value & Analysis

Healthcare · KR · Market cap 296B KRW

A solid business, screening 135% undervalued on our models.

What matters now

• The price is below even our cautious bear case (43,861 KRW). The market is more pessimistic than our downside scenario.
• Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 14,641 KRW – 74,638 KRW · fair‑value band 43,861 KRW – 73,102 KRW · the 24,850 KRW price screens below the 58,482 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Huons Global Co (084110) currently trades at 24,850 KRW, while our model-based Fair Value estimate is 58,482 KRW, implying the stock looks roughly 135.3% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Huons Global Co generated revenue of 659B KRW at a net margin of -0.1%. Revenue grew 17.5% year over year. Net debt stands at 110B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 43,861 KRW (bear case) to 73,102 KRW (bull case); at 24,850 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 135%, 084110 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth DCF (132,588 KRW) versus Asset-Based (33,765 KRW). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, …

Full company description

Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and injections in the areas of anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and others, as well as circulatory, respiratory, and other tissue cell systems. It also provides medical devices, eye drop products, and bio products. The company was formerly known as Huons Co., Ltd. and changed its name to Huons Global Co., Ltd. in June 2016. Huons Global Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Huons Global Co reported revenue of 847B KRW in FY2025 versus 575B KRW in FY2021, a compound +10.2%/yr. Reported net income was 28.8B KRW in FY2025, compounding +63.9%/yr from FY2021.

Watch 084110: get an alert when its fair value changes →

Peer Group

Pharmaceuticals · 25 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Pharmaceuticals median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.